Kiniksa Pharmaceuticals Ltd (OQ:KNSA)

Oct 06, 2020 08:00 am ET
Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways across a spectrum of diseases, announced positive data from the global Phase...
Sep 24, 2020 04:12 pm ET
Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the...
Sep 21, 2020 08:00 am ET
Kiniksa Announces Upcoming Rilonacept Analyst Day
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the...
Sep 15, 2020 08:00 am ET
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the...
Sep 09, 2020 04:01 pm ET
Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16th, 2020 at 2:00 p.m. Eastern Time. A live webcast of Kiniksa’s presentation...
Aug 31, 2020 08:00 am ET
Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, presented findings from...
Aug 04, 2020 08:00 am ET
Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11th, 2020 at 1:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be...
Jul 30, 2020 07:30 am ET
Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported second...
Jul 21, 2020 09:55 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381 Class A common shares at a public offering price of $21.00 per share, before underwriting discounts and...
Jul 20, 2020 04:07 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100.0 million of Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to...
Jul 16, 2020 07:30 am ET
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the...
Jun 29, 2020 07:15 am ET
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, reported positive data...
Jun 17, 2020 08:00 am ET
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that...
Jun 10, 2020 08:00 am ET
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that...
Jun 08, 2020 08:00 am ET
Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced the...
Jun 04, 2020 08:00 am ET
Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 at 3:00 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be...
May 29, 2020 08:30 am ET
Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced an...
May 18, 2020 04:01 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 of its Class A common shares at a public offering price of $18.25 per share, which includes the exercise in...
May 13, 2020 11:12 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 2,400,000 of its Class A common shares at a public offering price of $18.25 per share, before underwriting discounts and...
May 13, 2020 05:12 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 1,800,000 of its Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to...
May 11, 2020 07:30 am ET
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today provided...
Apr 28, 2020 07:30 am ET
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported first...
Apr 22, 2020 08:00 am ET
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced data...
Mar 31, 2020 08:15 am ET
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced early...
Mar 30, 2020 07:30 am ET
Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Ses
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, recently highlighted a...
Feb 26, 2020 07:30 am ET
Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported fourth...
Jan 13, 2020 08:00 am ET
Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced recent...
Dec 11, 2019 08:30 am ET
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), and Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”) announced today that the companies have entered into a clinical collaboration to conduct a Phase 2, multicenter study of mavrilimumab, an...
Dec 11, 2019 08:30 am ET
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), and Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”) announced today that the companies have entered into a clinical collaboration to conduct a Phase 2, multicenter study of mavrilimumab, an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma. The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta
Dec 10, 2019 08:00 am ET
Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:00...
Nov 20, 2019 04:01 pm ET
Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, 2019 at 3:30 p.m. Eastern Time at the Four Seasons Hotel in Boston, MA. A live...
Nov 20, 2019 08:00 am ET
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the...
Nov 16, 2019 12:00 pm ET
Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, reported final data from...
Nov 12, 2019 04:01 pm ET
Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
Oct 28, 2019 04:01 pm ET
Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported third...
Sep 19, 2019 04:01 pm ET
Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
Aug 19, 2019 07:30 am ET
Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
Aug 12, 2019 04:02 pm ET
Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported second...
Aug 12, 2019 04:01 pm ET
Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced interim...
Aug 06, 2019 07:30 am ET
Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13th, 2019 at 12:45...
Aug 05, 2019 07:30 am ET
Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced a...
Jun 12, 2019 07:30 am ET
Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology 
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
May 30, 2019 04:01 pm ET
Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
May 29, 2019 04:01 pm ET
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the following investor conferences in June: Jefferies 2019 Global Healthcare Conference on Wednesday, June 5th at 10:00 a.m. Eastern Time in New York, NY.Goldman...
May 16, 2019 07:30 am ET
Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, will present data from a...
May 13, 2019 07:30 am ET
Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
May 02, 2019 07:30 am ET
Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported first...
Apr 17, 2019 04:25 pm ET
Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
Apr 08, 2019 04:01 pm ET
Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it...
Mar 18, 2019 07:30 am ET
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, reported additional...
Mar 07, 2019 07:30 am ET
Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported fourth...
Feb 28, 2019 07:30 am ET
Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13th at 8:00 a.m. Eastern Time at The Boston Marriott Copley Place in Boston, MA. A...
Feb 26, 2019 07:30 am ET
Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Barclays Global Healthcare Conference on Tuesday, March 12th, 2019 at 8:30 a.m. Eastern Time at the Loews Miami Beach Hotel in Miami, FL. A live webcast of...
Jan 31, 2019 08:57 am ET
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”, “we”, and “our”) announced today the pricing of its public offering of 2,654,984 Class A common shares at a public offering price of $18.26 per share, before underwriting discounts and...
Jan 28, 2019 05:23 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase...
Jan 03, 2019 07:30 am ET
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational new drug application (IND) with the...
Dec 17, 2018 08:36 am ET
Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time at the Westin St. Francis Hotel in...
Dec 11, 2018 07:30 am ET
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced interim data from an open-label Phase 2 clinical trial of...
Dec 06, 2018 08:00 am ET
Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline consisting of five product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions, today announced...
Nov 15, 2018 07:35 am ET
Detailed Research: Economic Perspectives on Knight-Swift Transportation, Benitec Biopharma, Eastern, Kiniksa Pharmaceuticals, Qualstar, and Nomura Holdings Inc ADR — What Drives Growth in Today's Comp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Knight-Swift Transportation Holdings Inc. (NYSE:KNX), Benitec Biopharma...
Nov 01, 2018 08:00 am ET
Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported third...
Sep 15, 2018 08:00 am ET
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented Phase...
Aug 29, 2018 07:30 am ET
Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today...
Aug 28, 2018 04:01 pm ET
Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will be presenting at the 2018 Wells Fargo Healthcare Conference on Thursday, September 6th, 2018 at 8:00 a.m. Eastern Time at The Westin Copley Place in Boston, MA. A live...
Aug 06, 2018 07:30 am ET
Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today...
Aug 02, 2018 04:01 pm ET
Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will be presenting at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14th, 2018 at 9:45 a.m. Eastern Time at The Parker New York in New York City. A live...
Jun 25, 2018 07:00 am ET
Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares
Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical needs, announced...
Jun 14, 2018 04:01 pm ET
Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) announced today that it will be presenting at the JMP Securities 2018 Life Sciences Conference on Thursday, June 21st, 2018 at 10:30 a.m. Eastern Time at the St. Regis New York in New York City. A live...
May 29, 2018 04:57 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering
Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”) announced today the closing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share. The gross proceeds from the offering were $152.6...
May 24, 2018 06:51 pm ET
Nasdaq Welcomes Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) to The Nasdaq Stock Market
Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA), a clinical-stage biopharmaceutical company, visited the Nasdaq MarketSite in Times Square today for its initial public offering (IPO) on The Nasdaq Stock Market. Kiniksa is a clinical-stage...
May 23, 2018 09:13 pm ET
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering
Kiniksa Pharmaceuticals, Ltd. (“Kiniksa”) announced today the pricing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share, before underwriting discounts and commissions. The gross...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.